{
  "ticker": "JNJ",
  "timestamp": "2025-12-01T10:25:54.498004",
  "analysis_date": "2025-06-03",
  "historical_mode": true,
  "summary": {
    "recommendations": {
      "technical": "BUY",
      "news": "BUY",
      "fundamental": "HOLD",
      "macro": "HOLD"
    },
    "valid_recommendations": {
      "technical": "BUY",
      "news": "BUY",
      "fundamental": "HOLD",
      "macro": "HOLD"
    },
    "confidence_levels": {
      "technical": "Medium",
      "news": "Low",
      "fundamental": "Medium",
      "macro": "Low"
    },
    "bull_signal_count": 37,
    "bear_signal_count": 11,
    "bull_rec_count": 2,
    "bear_rec_count": 0,
    "hold_rec_count": 2,
    "undetermined_count": 0,
    "analyst_count": 4,
    "valid_analyst_count": 4,
    "net_sentiment": "BULLISH"
  },
  "analyst_summaries": {
    "technical": "TECHNICAL: Uptrend confirmed, RSI 14 \u2192 BUY (Medium)",
    "news": "NEWS: Bullish sentiment (54 articles) \u2192 BUY (Low)",
    "fundamental": "FUNDAMENTAL: Mixed fundamentals \u2192 HOLD (Medium)",
    "macro": "MACRO: Mixed macro \u2192 HOLD (Low)"
  },
  "full_analyst_reports": {
    "technical": "[TECHNICAL] *** HISTORICAL MODE: Analyzing as of 2025-06-03 ***\n\n======================================================================\nTECHNICAL ANALYSIS: JNJ\nAnalysis Period: 7 days\n*** HISTORICAL MODE: As of 2025-06-03 ***\nTimestamp: 2025-12-01 10:24:29\n======================================================================\n\n[TECHNICAL] Fetching 7-day price data for JNJ...\n[TECHNICAL] \u2713 Historical: 51 days ending 2025-06-03\n[TECHNICAL]   Date range: 2025-03-21 to 2025-06-03\n[TECHNICAL] \u2713 Retrieved 51 days of data\n[TECHNICAL] Calculating technical indicators...\n[TECHNICAL] \u2713 Indicators calculated\n[TECHNICAL] Identifying support/resistance levels...\n[TECHNICAL] \u2713 Support: $142.91, Resistance: $154.48\n[TECHNICAL] Formatting technical summary...\n[TECHNICAL] Generating analysis with gpt-4o-mini...\n[TECHNICAL] \u274c LLM error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n[TECHNICAL] Creating fallback analysis...\n\n[TECHNICAL] \u2713 Analysis complete in 18.86s\n======================================================================\n\n## Technical Analysis\n*Generated using fallback analysis (LLM unavailable)*\n\n\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-03 \u26a0\ufe0f**\nAll data below is historical, ending on 2025-06-03.\nDo NOT reference any price movements or events after this date.\n\n# Technical Analysis Data for JNJ\n\n**Analysis Period:** 7 days (Data: 51 days available)\n**Date:** 2025-06-03\n\n## Price Action\n- **Current Price:** $152.33\n- **Period Change:** +1.83%\n- **Day's Range:** $151.99 - $153.55\n- **Volume:** 8,209,800\n- **Volume Assessment:** Normal levels\n\n## Momentum Indicators\n- **RSI(14):** 71.2 \u2192 **OVERBOUGHT** (Potential pullback) \u26a0\ufe0f\n- **MACD:** 0.142 | Signal: -0.482 | Histogram: 0.624\n  \u2192 Bullish momentum \u2713\n- **Stochastic:** %K=88.1, %D=93.5\n  \u2192 Overbought territory\n\n## Moving Average Analysis\n- **SMA_5:** $152.12 (Above \u2713)\n- **EMA_10:** $151.32 (Above \u2713)\n- **SMA_20:** $150.07 (Above \u2713)\n- **SMA_50:** $151.66 (Above \u2713)\n\n**Trend:** Strong uptrend (price above all MAs) \u2713\n\n## Volatility & Range\n- **Bollinger Bands:** $144.62 < $152.33 < $155.51\n  \u2192 Middle range (71% position)\n- **ATR:** $2.13 (1.40% of price)\n  \u2192 Low volatility (tight stops possible) \u2713\n\n## Support & Resistance\n- **Key Resistance:** $154.48\n- **Secondary Resistance:** $153.60\n- **Key Support:** $142.91\n- **Secondary Support:** $144.10\n\n- **Distance to Resistance:** +1.4%\n- **Distance to Support:** +6.6%\n\n## Potential Trade Setup\n- **Setup Type:** LONG\n- **Entry:** $152.33\n- **Stop Loss:** $149.13 (Risk: $3.19)\n- **Target:** $154.48 (Reward: $2.15)\n- **Risk/Reward Ratio:** 0.67:1\n  \u2192 Poor risk/reward \u26a0\ufe0f\n\n\n---\n\n## Automated Assessment\n\n**Signals Detected:** 2 bullish, 0 bearish\n**Reasoning:** Multiple bullish signals: Strong uptrend, Price above MAs\n\nRECOMMENDATION: BUY - Confidence: Medium\n\n",
    "news": "[NEWS] *** HISTORICAL MODE: Analyzing as of 2025-06-03 ***\n\n======================================================================\nNEWS & SENTIMENT ANALYSIS: JNJ\n*** HISTORICAL MODE: As of 2025-06-03 ***\nPeriod: Last 7 days | Sources: ['yahoo', 'finnhub']\nTimestamp: 2025-12-01 10:24:51\n======================================================================\n\n[NEWS] \ud83d\udd27 Fetching Yahoo Finance news...\n[NEWS] \u26a0\ufe0f Yahoo Finance has limited historical news support\n[NEWS] \u2713 Yahoo Finance: 0 articles\n[NEWS] \ud83d\udd27 Fetching Finnhub news...\n[NEWS] Finnhub: Fetching news from 2025-05-27 to 2025-06-03\n[NEWS] \u2713 Finnhub: 54 articles\n[NEWS] \ud83d\udccb Enhancing 54 articles with background context\n[NEWS] \u26a0\ufe0f Date 2025-06-03 is past LLM knowledge cutoff (2024-01-01)\n[NEWS] \u26a0\ufe0f Skipping LLM context to prevent hallucination\n[NEWS] Analyzing with gpt-4o-mini...\n[NEWS] \u274c LLM error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n[NEWS] Creating fallback analysis...\n\n[NEWS] \u2713 Analysis complete in 18.68s\n======================================================================\n\n# News & Sentiment Analysis: JNJ\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-03 \u26a0\ufe0f**\n**Analysis Period:** Last 7 Days\n**Date:** 2025-12-01 10:24\n\n======================================================================\n\n## Yahoo Finance News (7 Days before 2025-06-03)\n\nNo news found in the specified period\n(Historical mode: news before 2025-06-03)\n## Finnhub News (2025-05-27 to 2025-06-03)\n\n**Found 54 articles**\n\n1. **Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts**\n   - Source: Yahoo\n   - Published: today\n   - Johnson & Johnson (JNJ) closed at $154.42 in the latest trading session, marking a -0.63% move from the prior day....\n\n2. **ASCO25: J&J\u2019s trispecific antibody shows 100% response in Phase I multiple myeloma study**\n   - Source: Yahoo\n   - Published: today\n   - First-in-human data for the trispecific antibody \u201csuggest a paradigm shift\u201d for the relapsed/refractory multiple myeloma space....\n\n3. **Johnson & Johnson's Darzalex Faspro Regimen Improves Progression-Free Survival in Two Phase 3 Myeloma Trials**\n   - Source: Yahoo\n   - Published: today\n   - Johnson & Johnson (JNJ) said Tuesday that data from two phase 3 trials show a Darzalex Faspro-based...\n\n4. **Single infusion of CARVYKTI\u00ae (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma**\n   - Source: Yahoo\n   - Published: today\n   - Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of pat...\n\n5. **DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity**\n   - Source: Yahoo\n   - Published: today\n   - Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)-based qu...\n\n6. **Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients**\n   - Source: Yahoo\n   - Published: today\n   - Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients ...\n\n7. **Why This 1 Value Stock Could Be a Great Addition to Your Portfolio**\n   - Source: Yahoo\n   - Published: today\n   - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....\n\n8. **Johnson & Johnson Says Akeega Has Potential to Slow Castration-Sensitive Prostate Cancer Growth**\n   - Source: Yahoo\n   - Published: today\n   - Johnson & Johnson (JNJ) said Tuesday that the first results from a phase 3 study showed that its Ake...\n\n\n======================================================================\n\n## News & Sentiment Analysis\n*Generated using fallback analysis (LLM unavailable)*\n*Historical analysis as of 2025-06-03*\n\n**Data Sources:** 2 successful, 0 failed\n\n**Sentiment:** BULLISH\n- Bullish signals: 1\n- Bearish signals: 0\n\n**Total Articles:** 54\n\nRECOMMENDATION: BUY - Confidence: Low\n\n",
    "fundamental": "[FUNDAMENTALS] *** HISTORICAL MODE: Analyzing as of 2025-06-03 ***\n\n======================================================================\nFUNDAMENTAL ANALYSIS: JNJ\n*** HISTORICAL MODE: As of 2025-06-03 ***\nTimestamp: 2025-12-01 10:25:12\n======================================================================\n\n[FUNDAMENTALS] Fetching comprehensive data for JNJ...\n[FUNDAMENTALS] \u2713 Comprehensive data retrieved\n[FUNDAMENTALS] Calculating historical metrics for 2025-06-03...\n[FUNDAMENTALS] \u2713 Historical metrics calculated: 4\n[FUNDAMENTALS]   - Price: $152.33\n[FUNDAMENTALS]   - P/E: 21.43\n[FUNDAMENTALS]   - P/B: 4.70\n[FUNDAMENTALS]   - Current Ratio: 1.26\n[FUNDAMENTALS] Analyzing earnings history...\n[FUNDAMENTALS] Filtering earnings to before 2025-06-03\n[FUNDAMENTALS] \u2713 Earnings analysis complete (4/4 beats)\n[FUNDAMENTALS] Fetching SEC 10-K filing data...\n[FUNDAMENTALS] Generating analysis with gpt-4o-mini...\n[FUNDAMENTALS] \u2713 Analysis generated (3049 chars)\n\n[FUNDAMENTALS] \u2713 Analysis complete in 16.59s\n======================================================================\n\n## Fundamental Analysis Summary\n**Overall Assessment:** Johnson & Johnson (JNJ) exhibits strong earnings growth and profitability metrics, but its valuation suggests it may be trading at a premium relative to its historical averages. \n\n## Key Findings\n### Valuation\n- The **Trailing P/E ratio** of **21.43** is reasonable considering the healthcare sector's typical valuations. However, without a PEG ratio, it\u2019s difficult to assess growth relative to price fully.\n- The **Price/Book ratio** of **4.70** indicates that the stock is trading at a premium compared to many of its peers in the sector, suggesting a higher investor expectation for growth.\n- The **Price/Sales ratio** of **5.39** and **EV/Revenue** of **5.71** further imply that the stock is valued on the higher end of the spectrum, which might be justified by its robust earnings growth.\n\n### Growth & Profitability  \n- JNJ has demonstrated impressive **earnings growth** of **91.0%**, which is particularly strong and indicates a significant improvement in profitability. However, **revenue growth** of **6.8%** suggests that while earnings are being managed well, revenue growth may not be as robust.\n- Profitability metrics are quite healthy, with a **profit margin** of **27.3%**, an **operating margin** of **30.2%**, and a **gross margin** of **68.4%**. These figures reflect operational efficiency and strong market positioning.\n- The **ROE of 33.6%** is significantly above the typical threshold of 15%, indicating high returns on shareholders' equity.\n\n### Financial Health\n- The **Current Ratio** of **1.26** indicates that the company has sufficient short-term assets to cover its liabilities, though it is below the ideal threshold of 1.5.\n- The **Debt/Equity ratio** of **57.77** suggests that the company has a moderate level of debt compared to equity; however, this is manageable within the healthcare sector.\n- Positive **Free Cash Flow** of **$12.01B** indicates that JNJ is generating sufficient cash to support operations and growth initiatives.\n\n### Earnings Quality\n- JNJ has a strong **earnings beat rate of 100%**, indicating that the company has consistently exceeded analyst expectations over the last four quarters. \n- However, the trend shows a **declining beat rate**, which could indicate that future earnings surprises may be less robust than in the past.\n\n## Investment Thesis\n**Bull Case:** \n1. Strong earnings growth (91%) and high profitability metrics (profit margin of 27.3%).\n2. High ROE (33.6%), which reflects efficient use of equity capital.\n3. Positive Free Cash Flow supports potential for future investments and shareholder returns.\n\n**Bear Case:** \n1. Valuation metrics suggest the stock is trading at a premium, which may limit upside potential.\n2. Slower revenue growth (6.8%) compared to earnings growth could raise concerns about sustainability.\n3. Declining trend in earnings beats may signal that future performance could be less predictable.\n\n## Final Recommendation\nRECOMMENDATION: HOLD - Confidence: Medium  \n**Risk Level:** Medium\n",
    "macro": "[MACRO] *** HISTORICAL MODE: Analyzing as of 2025-06-03 ***\n\n======================================================================\nMACRO ECONOMIC ANALYSIS\nPeriod: 7 days | Sector: All\n*** HISTORICAL MODE: As of 2025-06-03 ***\nTimestamp: 2025-12-01 10:25:31\n======================================================================\n\n[MACRO] Starting iterative analysis...\n[MACRO] Iteration 1/10\n[MACRO] \ud83d\udd27 Executing: get_market_indicators\n[MACRO] \ud83d\udd27 Tool: get_market_indicators (days=7)\n[MACRO] \u2713 Fetched 6/6 indicators\n[MACRO] \ud83d\udd27 Executing: get_sector_performance\n[MACRO] \ud83d\udd27 Tool: get_sector_performance (days=7)\n[MACRO] \u2713 Analyzed 9/9 sectors\n[MACRO] \ud83d\udd27 Executing: get_economic_indicators\n[MACRO] \ud83d\udd27 Tool: get_economic_indicators (days=7)\n[MACRO] \u2713 Economic indicators retrieved\n[MACRO] \ud83d\udd27 Executing: get_market_breadth\n[MACRO] \ud83d\udd27 Tool: get_market_breadth (days=7)\n[MACRO] \u2713 Breadth analysis complete\n[MACRO] Iteration 2/10\n[MACRO] \u274c Error in iterative analysis: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n\n[MACRO] \u2713 Complete in 23.13s\n======================================================================\n\n# Macro Analysis (Partial)\n*Analysis Period: 7 days*\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-03**\n*Successful Tools: 4, Failed: 0*\n\nRaw data gathered successfully:\n\nTools executed: get_market_indicators, get_sector_performance, get_economic_indicators, get_market_breadth\n\nRECOMMENDATION: NEUTRAL - Confidence: Low (Partial data)\n\n"
  },
  "bull_evidence": [
    {
      "source": "technical",
      "signal": "\u2192 Bullish momentum \u2713",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "technical",
      "signal": "**Reasoning:** Multiple bullish signals: Strong uptrend, Price above MAs",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "technical",
      "signal": "[TECHNICAL] \u2713 Support: $142",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "## Momentum Indicators",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "**Trend:** Strong uptrend (price above all MAs) \u2713",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Key Support:** $142",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Secondary Support:** $144",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Distance to Support:** +6",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "RECOMMENDATION: BUY - Confidence: Medium",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "[NEWS] \u26a0\ufe0f Yahoo Finance has limited historical news support",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Johnson & Johnson Says Akeega Has Potential to Slow Castration-Sensitive Prostate Cancer Growth**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Sentiment:** BULLISH",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Bullish signals: 1",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "RECOMMENDATION: BUY - Confidence: Low",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "- JNJ has a strong **earnings beat rate of 100%**, indicating that the company has consistently exceeded analyst expectations over the last four quarters",
      "strength": 3,
      "keywords_matched": 3
    },
    {
      "source": "fundamental",
      "signal": "**Overall Assessment:** Johnson & Johnson (JNJ) exhibits strong earnings growth and profitability metrics, but its valuation suggests it may be trading at a premium relative to its historical averages",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "fundamental",
      "signal": "01B** indicates that JNJ is generating sufficient cash to support operations and growth initiatives",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "fundamental",
      "signal": "Strong earnings growth (91%) and high profitability metrics (profit margin of 27",
      "strength": 2,
      "keywords_matched": 2
    }
  ],
  "bear_evidence": [
    {
      "source": "technical",
      "signal": "91, Resistance: $154",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "2 \u2192 **OVERBOUGHT** (Potential pullback) \u26a0\ufe0f",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "\u2192 Overbought territory",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Key Resistance:** $154",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Secondary Resistance:** $153",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Distance to Resistance:** +1",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Risk/Reward Ratio:** 0",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "\u2192 Poor risk/reward \u26a0\ufe0f",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Single infusion of CARVYKTI\u00ae (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Bearish signals: 0",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "**Risk Level:** Medium",
      "strength": 1,
      "keywords_matched": 1
    }
  ],
  "key_conflicts": [
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "fundamental",
        "technical"
      ],
      "positions": {
        "fundamental": "HOLD",
        "technical": "BUY"
      },
      "description": "fundamental says HOLD while technical says BUY"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "fundamental",
        "news"
      ],
      "positions": {
        "fundamental": "HOLD",
        "news": "BUY"
      },
      "description": "fundamental says HOLD while news says BUY"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "macro",
        "technical"
      ],
      "positions": {
        "macro": "HOLD",
        "technical": "BUY"
      },
      "description": "macro says HOLD while technical says BUY"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "macro",
        "news"
      ],
      "positions": {
        "macro": "HOLD",
        "news": "BUY"
      },
      "description": "macro says HOLD while news says BUY"
    }
  ],
  "consensus_points": [
    {
      "type": "partial_consensus",
      "recommendation": "BUY",
      "count": 2,
      "analysts": [
        "technical",
        "news"
      ],
      "description": "Partial consensus: technical and news both say BUY"
    },
    {
      "type": "partial_consensus",
      "recommendation": "HOLD",
      "count": 2,
      "analysts": [
        "fundamental",
        "macro"
      ],
      "description": "Partial consensus: fundamental and macro both say HOLD"
    }
  ],
  "research_priorities": [
    {
      "priority": "HIGH",
      "focus": "validate_bull_thesis",
      "description": "Strong bullish bias (37 vs 11 signals)",
      "action": "Validate assumptions - could be herd mentality or overlooked risks"
    },
    {
      "priority": "URGENT",
      "focus": "time_sensitive_event",
      "description": "Upcoming catalyst detected",
      "signal": "- JNJ has a strong **earnings beat rate of 100%**, indicating that the company has consistently exceeded analyst expectations over the last four quarters",
      "source": "fundamental",
      "action": "Research before event occurs"
    }
  ],
  "analyst_reports_summary": {
    "technical": {
      "recommendation": "BUY",
      "confidence": "Medium",
      "report_length": 3092,
      "has_data": true,
      "completed_successfully": true
    },
    "news": {
      "recommendation": "BUY",
      "confidence": "Low",
      "report_length": 4604,
      "has_data": true,
      "completed_successfully": true
    },
    "fundamental": {
      "recommendation": "HOLD",
      "confidence": "Medium",
      "report_length": 4132,
      "has_data": true,
      "completed_successfully": true
    },
    "macro": {
      "recommendation": "HOLD",
      "confidence": "Low",
      "report_length": 1737,
      "has_data": true,
      "completed_successfully": true
    }
  },
  "data_quality": {
    "status": "COMPLETE",
    "total_analysts": 4,
    "valid_analysts": 4,
    "failed_analysts": 0,
    "failed_list": [],
    "note": null
  },
  "llm_synthesis": "Synthesis error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
  "synthesis_direction": "UNDETERMINED",
  "synthesis_confidence": "N/A"
}